Clinical trial · Expanded Access
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors Harboring NTRK Fusion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Selitrectinib (BAY2731954) | Drug | Selitrectinib | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Month
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion * Previous treatment with a kinase inhibitor with known activity on TRK inhibition * Unable to participate in an ongoing selitrectinib clinical trial * Medically suitable for treatment with selitrectinib Exclusion Criteria: * Currently enrolled in an ongoing clinical study with a TRK inhibitor
References
Publications (0)
Data not yet available